Effect of Different Hyaluronic Acids in the Treatment of Subdeltoid Bursitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ultra-high molecular weight hyaluronic acid injection, high molecular weight hyaluronic acid injection.
- Who it may be relevant to
- Registry conditions: Subdeltoid Bursitis of the Shoulder. Basic parameters: from 20 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Different Molecular-Weight Hyaluronic Acid in the Treatment of Subdeltoid Bursitis: A Double-Blind Randomized Controlled Trial
Overview
The study employs a double-blind, randomized clinical trial design with 50 patients diagnosed with subdeltoid bursitis. Participants are divided into two groups: ultra-high-molecular-weight hyaluronic acid or high-molecular-weight hyaluronic acid injection. All injections are guided by ultrasound. Assessments are conducted before treatment and at 1 week, 1 month, and 3 months post-treatment.
Detailed description
Evaluation indicators include pain (measured by Visual Analog Scale), function (assessed by Disabilities of the Arm, Shoulder, and Hand score and Shoulder Pain and Disability Index), quality of life (using the World Health Organization Quality of Life-BREF).
Interventions
- Drug ultra-high molecular weight hyaluronic acid injection
ultra-high molecular weight hyaluronic acid - Drug high molecular weight hyaluronic acid injection
Ultrasound-guided injection into subdeltoid bursa
Primary outcome measures
- Shoulder Pain and Disability Index [Time frame: Score change from baseline to 1 week, 1 months and 3 months of treatment, higher score, the better outcome]
Secondary outcome measures (4)
- Disabilities of the Arm, Shoulder, and Hand [Time frame: Score change from baseline to 1 week, 1 months and 3 months of treatment, higher score, the better outcome]
- Range of motions of shoulder joint [Time frame: Score change from baseline to 1 week, 1 months and 3 months of treatment, higher score, the better outcome]
- World Health Organization Quality of Life [Time frame: Score change from baseline to 1 week, 1 months and 3 months of treatment, higher score, the better outcome]
- visual analog scale [Time frame: Score change from baseline to 1 week, 1 months and 3 months of treatment, higher score, the better outcome]
Eligibility criteria
Inclusion criteria
Unilateral shoulder pain within the past 3 months
Pain during joint movements such as abduction or internal rotation
At least one positive result from the following tests: Painful arc, Neer test, or Hawkins test
No shoulder injections received in the past 3 months
Willingness to receive injection treatment and undergo follow-up assessments
Avoid use of anti-inflammatory painkillers during the study period as much as possible; if intolerable pain occurs, acetaminophen (provided by the researcher) will be used to relieve symptoms
Exclusion criteria
Presence of infectious disease, inflammation, rheumatoid arthritis, or fracture
History of malignancy
Previous shoulder surgery
Sensory deficits
Total tendon rupture of the rotator cuff or biceps tendon
Neurological disorders causing hand weakness or affecting shoulder mobility (e.g., stroke, Parkinson's disease, brachial plexus injury, peripheral neuropathy) Cognitive impairment preventing completion of questionnaires
Cervical radiculopathy
Diagnosed frozen shoulder (adhesive capsulitis)
Psychiatric disorders
Breastfeeding or pregnant women
Received shoulder injection within the past 3 months, including corticosteroids, hyaluronic acid, Platelet-rich plasma, or any prolotherapy solution
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07729514 · 2026SKHADR035